Bupropion and Counseling With or Without Contingency Management to Enhance Smoking Cessation in Treating Cancer Survivors Who Continue to Smoke - Full Text View

Purpose

RATIONALE: Contingency management is a behavioral treatment approach that provides immediate rewards for positive change in behavior such as quitting smoking. In this protocol, contingency management will be in the form of a cash reward. A smoking cessation (stop-smoking) program that combines contingency management with bupropion and counseling may be effective in helping cancer survivors stop smoking.

PURPOSE: Randomized clinical trial to compare the effectiveness of bupropion and counseling with or without contingency management in helping cancer survivors stop smoking.

Condition	Intervention
Cancer Survivor Unspecified Adult Solid Tumor, Protocol Specific	Behavioral: smoking cessation intervention Drug: bupropion hydrochloride


Study Type:	Interventional
Study Design:	Allocation: Randomized Primary Purpose: Prevention
Official Title:	Contingency Management to Enhance Smoking Cessation for Cancer Survivors: A Proof of Concept Trial

Resource links provided by NLM:

MedlinePlus related topics: Quitting Smoking Smoking

Drug Information available for: Bupropion hydrochloride Bupropion

U.S. FDA Resources

Further study details as provided by National Institutes of Health Clinical Center (CC):


Study Start Date:	February 2004
Study Completion Date:	August 2004

Detailed Description:

OBJECTIVES:

Primary

Compare the feasibility of a multi-component smoking cessation intervention comprising bupropion and counseling with or without contingency management (cash reward) for cancer survivors who continue to smoke.
Compare 7-day point-prevalence abstinence rates in patients treated with these smoking cessation interventions.

Secondary

Determine the characteristics of these patients that predict success at quitting smoking.

OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 smoking cessation intervention arms.

Arm I: Patients receive oral bupropion twice daily on weeks 1-12 and brief practical counseling (i.e., problem-solving strategies, stimulus control, stress management, and social support) on weeks 1-6.
Arm II: Patients receive treatment as in arm I and contingency management (i.e., monetary reinforcement for not smoking) on weeks 1-6.

In both arms, treatment continues in the absence of unacceptable toxicity.

Patients are followed at 12 and 24 weeks after the completion of the smoking cessation interventions.

PROJECTED ACCRUAL: A total of 100 patients (50 per intervention arm) will be accrued for this study within 8 months.

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Diagnosis of cancer at least 6 months before study entry
- No carcinoma in situ of the cervix, basal cell or squamous cell skin cancer, or CNS tumor
Smoking history of at least 2 years
- Smoked cigarettes daily for the past 30 days
Completed prior cancer treatment at least 6 months, but no more than 5 years before study entry
- Concurrent tamoxifen allowed

PATIENT CHARACTERISTICS:

Age

18 and over

Performance status

Not specified

Life expectancy

Not specified

Hematopoietic

Platelet count ≥ 100,000 - 450,000/mm^3
WBC ≥ 3,000/mm^3

Hepatic

AST and ALT ≤ 2 times upper limit of normal
Bilirubin ≤ 2.0 mg/dL

Renal

Creatinine < 2.0 mg/dL

Cardiovascular

No unstable cardiovascular disease, including any of the following:
- High-grade atrioventricular block
- Neurocardiogenic syncope
- Unstable angina
- Uncompensated congestive heart failure
- Poorly controlled hypertension

Other

Not pregnant or nursing
Negative pregnancy test
Able to undergo peripheral blood draw
- No port-a-cath or Hickman catheters
Planning to reside in the Washington D.C. metro area for at least 1 year after study entry
Willing to undergo urine testing for cotinine levels and breath testing for carbon monoxide monitoring
No significant physical or psychological disability that would preclude study participation
No known allergy to bupropion
Baseline urine drug screen negative
- Prescribed pain medication allowed
None of the following predisposing factors that may increase the risk of seizures with bupropion use:
- History of seizures
- Alcohol use > 4 oz/day
- History of closed head injury
- History of an eating disorder
- CNS infection
No poorly controlled diabetes

PRIOR CONCURRENT THERAPY:

Biologic therapy

Not specified

Chemotherapy

Not specified

Endocrine therapy

See Disease Characteristics

Radiotherapy

Not specified

Surgery

Not specified

Other

At least 2 years since prior alcohol abuse or substance abuse therapy (except for tobacco use or dependence)
More than 14 days since prior monoamine oxidase (MAO) inhibitor
No concurrent MAO inhibitor
No concurrent bupropion (Wellbutrin® or Wellbutrin SR®)
No concurrent alcohol or substance abuse disorder treatment
No concurrent nicotine replacement therapy
No concurrent medications that lower seizure threshold (e.g., theophylline or short-acting benzodiazepines)
No use of tobacco products (more than 1 time per week) other than cigarettes

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00079469

Locations


United States, Maryland
Tobacco Control Research Branch
Rockville, Maryland, United States, 20852

Sponsors and Collaborators

National Institutes of Health Clinical Center (CC)

National Cancer Institute (NCI)

Investigators


Principal Investigator:	Glen D. Morgan, PhD	NCI - Division of Cancer Control and Population Science
OverallOfficial:	Sandra J. Schaefer, RN, BSN, OCN	National Cancer Institute (NCI)

More Information


ClinicalTrials.gov Identifier:	NCT00079469 History of Changes
Other Study ID Numbers:	999903308 03-C-N308 CDR0000356037
Study First Received:	March 8, 2004
Last Updated:	March 7, 2012

Keywords provided by National Institutes of Health Clinical Center (CC):


cancer survivor unspecified adult solid tumor, protocol specific

Additional relevant MeSH terms:


Bupropion Antidepressive Agents, Second-Generation Antidepressive Agents Psychotropic Drugs Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators	Molecular Mechanisms of Pharmacological Action Dopamine Agents Neurotransmitter Agents Physiological Effects of Drugs Cytochrome P-450 CYP2D6 Inhibitors Cytochrome P-450 Enzyme Inhibitors Enzyme Inhibitors

ClinicalTrials.gov processed this record on June 26, 2017